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Sex Med 2We report on the 1st case of ischemic priapism secondary to poorly controlled homocystinuria. Homocystinuria is a
rare, autosomal recessive, inherited disorder of metabolism that is caused by a deﬁciency of cystathionine synthase,
leading to marked hyperhomocysteinemia. Arterial and/or venous thromboemboli are a major cause of mortality and
morbidity in patients with homocystinuria. Untreated patients have a 50% chance of having a vascular event by 30
years of age. Increased homocysteine levels have been reported to upregulate prothrombotic factors and downregulate
antithrombotic factors; in particular, increased homocystinuria has been found to downregulate nitric oxide (NO).
Mice that are deﬁcient in NO synthase in the cavernosal smooth muscles have a higher incidence of priapism. Decrease
in NO synthase causes downregulation of cyclic guanosine monophosphate, phosphodiesterase type 5A, and Rho A/
Rho-kinase. Because persistently increased homocysteine also downregulates NO, a similar mechanism could be
proposed for priapism secondary to homocystinuria. In patients presenting with priapism, speciﬁc features of homo-
cystinuria should be sought; in selected patients, screening with plasma total homocysteine might be appropriate.
Ischemic priapism secondary to homocystinuria appears to respond well to the standard treatment options of aspiration,
intracavernosal injection with phenylephrine, and, if required, a shunting procedure. Johnson M, Murphy E, Raheem
A, Ralph D. Poorly Controlled Homocystinuria: A Rare Cause of Ischemic Priapism? Sex Med 2018;6:171e173.
Crown Copyright  2018, Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ischemic priapism is a compartment syndrome of the corpus
cavernosa. It is characterized by a persistent painful penile erection
lasting longer than 4 hours that is not associated with sexual arousal.
Inadequate or delayed treatment will result in permanent erectile
dysfunction and penile shortening. Ischemic priapism is most often
associated with sickle cell disease and can be caused by certain drugs,
spinal injury, and malignancy. In addition, there are a signiﬁcant
number of men with idiopathic ischemic priapism in whom no
cause is identiﬁed.1 Identiﬁcation of novel causes of priapismwill aid
our understanding of this potentially devastating condition.
To our knowledge, this is the 1st reported case of ischemic pri-
apism that is likely secondary to poorly controlled homocystinuria.tober 16, 2017. Accepted December 20, 2017.
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018;6:171e173Homocystinuria is a rare inherited condition that results in an
increased plasma homocysteine level, which is a signiﬁcant risk
factor for arterial and venous thromboemboli.2 Ischemic priapism
results from prolonged veno-occlusion and thrombosis of the corpus
cavernosa.1CASE REPORT
A 34-year-old man with poorly controlled homocystinuria
presented to his local emergency department with a 24-hour
history of ischemic priapism. This was the patient’s 1st episode
of priapism and his late presentation was attributed to his lack
of knowledge of the condition. Successful detumescence was
achieved with immediate corporal aspiration, washout, and
intracavernosal injection of phenylephrine 400 mg. Cavernosal
blood gas analysis was consistent with ischemic priapism
(pH ¼ 6.9, PCO2 ¼ 15.28 KPa, PO2 < 1.3 KPa, lactate ¼ 13.4
mmol/L [reference range ¼ 0.5e2.2 mmol/L]). However, 3
hours after the initial intervention, his priapism recurred. Repeat
aspiration, washout, and intracavernosal injection of phenyl-
ephrine were unsuccessful and he was taken to the theater and
successfully underwent an emergency bilateral trans-glandular
cavernosum-spongiosum shunt.171
172 Johnson et alAfter his discharge, the patient reported 1 to 2 episodes
of stuttering priapism each week (self-limiting episodes of pro-
longed penile erection), which he managed conservatively with
exercise. 2 months after his original presentation with priapism,
the patient presented again with a painful 4-hour penile erection.
This time successful detumescence was achieved with aspiration
and intracavernosal injection with phenylephrine. Cavernosal
blood gas analysis again showed an acidotic, hypoxic, and hy-
percapnic blood gas picture consistent with ischemic priapism.
The patient was discharged with 1 month of cyproterone acetate
100 mg once daily (OD; antiandrogen) to prevent further epi-
sodes of priapism. After stopping the cyproterone acetate and
despite these 2 episodes of priapism, the patient reported normal
erectile function.
The patient has a background history of homocystinuria and
asthma. His homocystinuria is complicated by bilateral aphakia,
decreased bone mineral density, and lower limb varicosities.
Prescribed medications included betaine 3 g 3 times daily, folic
acid 5 mg OD, pyridoxine 100 mg OD, hydroxocobalamin
1-mg injection 3 times monthly, aspirin 75 mg OD, calcium and
vitamin D supplements, and inhalers. However, he admitted
long-standing poor adherence to all prescribed medications.
Biochemical testing at the time of his 1st episode of priapism
was consistent with poorly controlled homocystinuria and
included increased levels of plasma total homocysteine (382
mmol/L, normal range ¼ 5e12 mmol/L), methionine (255
mmol/L, normal range ¼ 13e40 mmol/L), and free homocystine
(106 mmol/L, normally not detectable). Hemoglobinopathy
screen, renal, liver, and bone proﬁles were normal. Secondary
abnormalities included a low to normal vitamin B12 level (210
pg/mL, normal range ¼ 197e771 pg/mL), a low serum
folate level (<2 ng/mL, normal range ¼ 2.9e26.8 ng/mL),
and an insufﬁcient total cysteine level (55 mmol/L, normal
range ¼ 200e350 mmol/L). Hemoglobin (144 g/L, normal
range ¼ 130e170 g/L) and mean corpuscular volume (94.1 ﬂ,
normal range ¼ 80e99 ﬂ) were normal.DISCUSSION
Homocystinuria is a rare, autosomal recessive, inherited dis-
order of metabolism that is caused by deﬁciency of cystathionine
b-synthase, leading to marked hyperhomocysteinemia. The
clinical presentation varies, with some patients presenting with
typical features in early childhood and others (particularly those
with a vitamin B6eresponsive form of the condition) remaining
asymptomatic until adulthood. Typically, it is a multisystem
disorder that can affect the (i) eyes (dislocation of the optic lens),
(ii) skeletal system (marfanoid habitus, with excessive height and
long limbs), (iii) vascular system (thromboemboli), and (iv)
central nervous system (learning difﬁculties).2
Arterial and/or venous thromboemboli are a major cause
of mortality and morbidity in patients with homocystinuria.
Untreated patients have a 50% chance of having a vascular eventby 30 years of age.3 Patients who achieve consistent lowering of
plasma homocysteine have a signiﬁcant decrease in the number
of vascular events experienced.4 Current recommendations for
treatment are to maintain plasma total homocysteine levels lower
than 100 mmol/L lifelong.2
Venous thrombosis is the most common vascular event in
homocystinuria. The exact pathophysiology of accelerated
vascular disease experienced by these patients is unclear.
Increased homocysteine levels have been reported to upregulate
prothrombotic factors and downregulate antithrombotic factors.
In vitro animal model data have shown that increased homo-
cysteine levels (i) increase platelet activation and aggregation;
(ii) block tissue plasminogen activator on the vascular endothe-
lium, resulting in impaired ﬁbrinolysis; (iii) bind to factor V,
preventing deactivation of activated protein C; and (iv) down-
regulate nitric oxide (NO), thus lessening its bioavailability.5
Priapism results from prolonged veno-occlusion and throm-
bosis of the corpus cavernosa. It is proposed that blood in the
erect penis (deoxygenated with increased carbon dioxide)
causes ischemia, which in turn causes venous congestion in the
sinusoidal space and increased viscosity.6 Mice that were deﬁ-
cient in NO synthase in cavernosal smooth muscles had a higher
incidence of priapism. Decrease in NO synthase causes down-
regulation of cyclic guanosine monophosphate, phosphodies-
terase type 5A, and Rho A/Rho-kinase.7,8 Because persistently
increased homocysteine also downregulates NO, a similar
mechanism could be proposed for priapism secondary to
homocystinuria.
Emergency and/or uncommon conditions often lack good-
quality evidence. Much of the evidence for ischemic priapism
has been conducted in vitro or in men with sickle cell disease.1
This case reports adds to the limited literature on this subject.
In patients presenting with priapism, speciﬁc features of
homocystinuria should be sought; in selected patients, screening
with plasma total homocysteine might be appropriate. Ischemic
priapism secondary to homocystinuria appears to respond well to
the standard treatment options of aspiration, intracavernosal
injection with phenylephrine, and, if required, a shunting
procedure.
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